Defining the Indications for Prophylactic Percutaneous Endoscopic Gastrostomy Tubes in Surgically Treated Head and Neck Cancer Patients by Jason Foster et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Defining the Indications for  
Prophylactic Percutaneous Endoscopic 
Gastrostomy Tubes in Surgically Treated  
Head and Neck Cancer Patients 
Jason Foster1, Peter Filocamo1, William Brady2,  
Thom Loree1 and John F. Gibbs1 
1Department of Surgery, Roswell Park Cancer Institute,  
State University of New York at Buffalo, Elm & Carlton Streets, Buffalo, NY  
2Department of Biostatics, Roswell Park Cancer Institute,  
State University of New York at Buffalo, Elm & Carlton Streets, Buffalo, NY 
U.S.A. 
1. Introduction 
Malnutrition is a common problem in head and neck cancer with up to 50%  of the patients 
developing some degree of nutritional deficiency.1 The etiologies of this problem can be 
divided into two categories: tumor related or treatment related. Patient with tumor related 
malnutrition typically present with obvious clinical signs and symptoms of 
undernourishment. Tumor cachexia can contribute but this is primarily caused by physical 
impediments to oral consumption such as pain, oropharygeal obstruction, or nerve 
compression , all resulting in discordant degluttination.2 Prior to definitive cancer therapy, 
this group of patients requires nutritional resuscitation. 
Additionally many patients who present nutritionally sound and who undergo surgical 
resection experience some degree of postoperative nutritional difficulties. In many cases it a 
short lived and inconsequential. However, a subset of patients will experience a more severe 
prolonged course requiring enteral supplementation. Prior studies have shown that if these 
patients are not supplemented, they will likely experience severe dehydration, treatment 
intolerance, or severe treatment related complications that require hospitalization.3,4 
Inherently, the surgical treatment of head and neck malignancies can be quite debilitating 
and result in significant mastication and deglutination dysfunction.5-7  At times this involves 
radical resections that require complex reconstructions to maintain oropharyngeal 
continuity; and adjuvant radiation and/or chemotherapy may be required to maximize local 
control. Indiscriminately placing PEG tubes in all patients would put many patients at risk 
for PEG related complications.8-13  Therefore, the difficulty has been trying to preoperatively 
identify which patients likely to experience prolonged treatment induced malnutrition and 
benefit from early nutritional supplementation. 
Groups have identified some factors that are predictive of a need for enteral support.3,4,14-17  




postoperatively.3,4,17  Other factors such as  Stage IV disease, base of tongue tumor location, 
and heavy alcohol ingestion are less clearly defined.14-16  Some criticisms have been that the 
studies conducted to identify these variables were small, used a mixed population of 
surgical and non-surgical patients, and often used durations of enteral support that were 
short (< 4 weeks) or undefined.  
At Roswell Park Cancer Institute (RPCI) prophylactic PEG are routinely placed in surgically 
treated patients who require a composite resection, flap reconstruction, radiation therapy, 
chemotherapy, and at the discretion of the attending surgical staff. We found that many 
patients required their PEG tube for 4 weeks or less; while some patients required their PEG 
for a year or longer. In order to more accurately define which patients benefited from 
prophylactic PEG placement we reviewed our experience. We used a homogenous 
population of surgically treated head and neck cancer patients to identified patient, tumor, 
and treatment factors that were predictive of a short-term (≤ 3 months) and long-term (≥1 
year) PEG tube dependency.  
2. Methods 
One hundred forty one cases of surgically treated head and neck cancers treated at RPCI 
from January 1, 1999 to December 31, 2003 who underwent pretreatment placement of PEG 
tubes were reviewed. Only patients with squamous cell carcinoma (SCC) of the oral cavity, 
oropharynx, larynx, and pharynx were included in this study eliminating 14 patients. 
Seven patients had PEG tube placed a second time for the treatment of a new primary or 
recurrent disease, and six patients did not have complete records, leaving 114 patients for 
evaluation.  
The variables analyzed were divided into patient factors (age and sex), tumor factors 
(primary site, T stage and nodal status), and treatment factors (flap reconstruction, 
radiation, and chemotherapy). A short-term dependency required that the PEG tube be in 
place for 3 months or less, while a long-term dependency require usage for a year or 
longer. 
2.1 Statistical method 
The duration of PEG tube dependency was calculated from the date of placement until the 
time of removal. Patients who had their PEG tube removed and not replaced were 
considered to be no longer dependent on it. Patients who died while still dependent on their 
PEG tube, or who were still dependent at last documented follow-up were considered to 
have censored durations. Because of this censoring, time to event analyses was used. The 
distribution of PEG duration was compared across age, sex, tumor sites, T stage, N stage, 
flap reconstruction, radiation, and chemotherapy. Kaplan-Meier estimates of the 
proportions (and 95% confidence intervals {CIs}) of patients with PEG tubes in place at 3 
and 12 months after placement were determined for each variable and log-rank tests were 
used to compare durations. 
Proportional hazards regression models were used to compare durations while accounting 
for other factors. Variables were selected for inclusion in the model in a stepwise selection 
process. Variables were entered in the model if p<0.05 and were retained if p<0.05. Because 
a number of patients had unknown T stage (8 patients) and unknown N stage (20 patients), 
in the proportional hazards regression models, these factors included separate levels for 
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‘unknown’ T and ‘unknown’ N stage, respectively. In the log-rank analyses of T stages and 
N stages, patients with unknown stages were not included. 
These analyses are post hoc so no adjustments for multiplicity are made. All tests were 
done two-sided with a significance level of 0.05. All analyses were done using SAS 
version 8.2. 
3. Results 
The mean age of patients in this study was 65 and 65% of patients were male. Sixty-four 
percent of the patients had advanced T stage or recurrent disease and node positive disease 
was present in 49% of the patients. Flap reconstructions were performed in 39% of patients, 
while the rate of adjuvant therapy was 40% for radiation and 11% for chemotherapy. The 
percentage of patients  in each of the four major tumor sites were 42% oral cavity, 23% 
oropharynx, 26% larynx, and 9% pharynx. In Table 1 the patient characteristics (age, sex), 
tumor characteristics (T stage, N stage), and treatment (flap reconstruction, radiation, 
chemotherapy) characteristic, along with PEG status at the end of the study is presented for 
each major tumor site. Overall 64% (73/114) of patients in the study had their PEG tubes 
removed. 
Sixty-nine percent of patients had short-term PEG usage. When the group receiving 
adjuvant radiation was compared to the group that did not receive radiation treatment a 
significant difference was observed 91% (83, 99) vs. 53% (41, 65). Eighty-nine percent of 
pharyngeal tumor site patient and 92% of chemotherapy patients had a short term 
dependency but this was not statistically different from the other tumors site or the no 
chemotherapy group respectively. The short-term dependency was not influenced by 
patient age, sex, T stage, N stage, or flap reconstruction (Table 2).  
The long-term dependency for this group of patients was 36%. Table 2 presents Kaplan-
Meier estimates of the proportions of patients with PEG tubes in place at 12 months for each 
variable. PEG tube duration was statistically significantly different across surgical sites: 78% 
of pharynx patients still had their tubes in place after 12 months, while only 45% of oral 
cavity patients, 34% of oropharynx patients, and 11% or larynx patients had tubes in place. 
Patients who underwent flap reconstruction also had statistically significantly (p=0.004) 
longer PEG tube durations than those who did not, 52% vs. 25%, respectively. When a 
multivariate analysis was performed, adjusting for other factors, site and flap reconstruction 
remained as statistically significantly long-term risk factors. Chemotherapy was also found 
to be significant factor in long-term PEG dependency.  
4. Discussion 
The prevention of malnutrition and early nutritional support in the management of cancer 
patients is well documented. Specifically in head and neck cancer, suboptimal nutrition 
during definitive treatment results in a significant increase in surgical complications, 
dehydration, therapy breaks and hospitalizations. (3). Because malnutrition can result in 
reduced immunosurvelliance, it may contribute to early local and distant cancer recurrence. 
(18, 19)  Avoidance of treatment induced malnutrition may prevent these complications, and 
prophylactic placement of PEG tube provides access for the delivery of nutrition. 
Identification of the risk factors which contribute to prolonged enteral support ensures 




factors can avoids subjecting low risk patients to PEG related complications, and costs. In 
this study we found that radiation was the only predictor of a short-term dependency; 
while pharyngeal tumor site, flap reconstruction, and chemotherapy were predictive a 




 Oral cavity Oropharynx Larynx Pharynx 
 n % n % n % n % n % 
All 49 26 30 9  114  
Removal Category 
Died 10 20 5 19 2 7 6 67 23 20 
In Use at End of Follow-up 11 22 4 15 1 3 1 11 17 15 
Removed 28 57 17 65 26 87 2 22 73 64 
Unknown/Loss to Follow-up 0 0 0 0 1 3 0 0 1 1 
Age, PEG Placed (y) 
<55 10 20 9 35 7 23 2 22 28 25 
55-64 10 20 8 31 12 40 3 33 33 29 
65-74 16 33 6 23 7 23 3 33 32 28 
>=75 13 27 3 12 4 13 1 11 21 18 
Sex 
F 24 49 5 19 8 27 3 33 40 35 
M 25 51 21 81 22 73 6 67 74 65 
Chemotherapy 
Unknown 1 2 0 0 0 0 0 0 1 1 
No 46 94 22 85 24 80 9 100 101 89 
Yes 2 4 4 15 6 20 0 0 12 11 
Radiation 
Unknown 1 2 0 0 0 0 0 0 1 1 
No 32 65 11 42 19 63 5 56 67 59 
Yes 16 33 15 58 11 37 4 44 46 40 
Flap Reconstruction 
No 34 69 7 27 25 83 3 33 69 61 
Yes 15 31 19 73 5 17 6 67 45 39 
T Stage 
Unknown 3 6 3 12 2 7 0 0 8 7 
Recurrence 14 29 7 27 9 30 0 0 30 26 
T1 2 4 1 4 2 0 2 22 5 4 
T2 16 33 6 23 5 17 1 11 28 25 
T3 5 10 7 27 11 37 4 44 27 24 
T4 9 18 2 8 3 10 2 22 16 14 
Node Involvement 
Unknown 6 12 6 23 6 20 0 0 18 16 
No 21 43 2 8 13 43 4 44 40 35 
Yes 22 45 18 59 11 37 5 56 56 49 
Table 1. Characteristics of Patients by Surgical Site 
www.intechopen.com
Defining the Indications for Prophylactic Percutaneous  







Percent† (95% CI) of Patients With 






3 months 12 months 
Site       
Oral cavity 49 11.2 (4.1, NE) 64% (51%, 78%) 45% (31%, 60%) 
0.007 0.004 
Oropharynx 26 6.6 (4.0, 18.2) 80% (64%, 96%) 34% (15%, 53%) 
Larynx 30 3.5 (2.6, 5.9) 62% (45%, 80%) 11% (0%, 23%) 
Pharynx 9 NE 89% (68%, 100%) 78% (51%, 100%) 
Age, PEG Placed (y)     
 <55 28 7.1 (4.7, 11.3) 78% (63%, 94%) 29% (11%, 47%) 
0.157 NA 
 55-64 33 3.1 (2.3, 6.6) 52% (34%, 69%) 26% (10%, 41%) 
 65-74 32 11.2 (5.0, NE) 87% (75%, 99%) 50% (31%, 68%) 
 ≥75 21 4.4 (2.6, 19.1) 60% (38%, 81%) 41% (18%, 64%) 
Sex       
F 40 5.0 (4.0, 11.2) 68% (54%, 83%) 32% (16%, 48%) 
0.583 NA 
M 74 6.6 (4.9, 11.3) 70% (59%, 80%) 37% (25%, 49%) 
Radiation       
No 67 3.2 (2.3, 8.7) 53% (41%, 65%) 34% (22%, 46%) 
0.102 NA 
Yes 46 8.2 (6.6, 13.8) 91% (83%, 99%) 38% (23%, 53%) 




5.9 (4.1, 8.7) 66% (57%, 76%) 35% (25%, 44%) 
0.141 <0.001 
Yes 12 10.6 (4.9, NE) 92% (76%, 100%) 46% (17%, 76%) 
Flap Reconstruction     
No 69 4.9 (2.7, 6.6) 62% (50%, 73%) 24% (13%, 35%) 
0.002 0.011 
Yes 45 18.2 (5.6, NE) 82% (70%, 93%) 54% (38%, 69%) 
T Stage       
Recurrence 30 5.9 (2.7, 18.2) 66% (49%, 83%) 42% (22%, 61%) 
0.151 NA 
T1 5 NE 80% (45%, 100%) 53% (5%, 100%) 
T2 28 6.3 (3.8, 11.3) 71% (55%, 88%) 27% (9%, 45%) 
T3 27 5.0 (2.6, 9.9) 66% (48%, 84%) 24% (7%, 41%) 
T4 16 NE 80% (60%, 100%) 60% (35%, 85%) 
Node Involvement     
No 40 5.4 (2.6, 8.7) 62% (47%, 77%) 33% (18%, 49%) 
0.663 NA 
Yes 56 6.6 (4.7, 11.2) 74% (63%, 86%) 30% (18%, 43%) 
¶ At PEG placement. 
† Percents and medians are Kaplan-Meier estimates. 
‡ From likelihood ratio tests for selected covariates from proportional hazards regression models using 
stepwise selection. 
NA = not applicable (term not selected for inclusion in proportional hazards regression model). 
NE = not estimable




Other groups have documented that radiation treatment results in significant 
malnutrition.(3,4,20)  Radiation treatment often results in xerostomia, loss of taste, 
mucositis, and tumor edema which all contribute to poor oral intake and nutritional deficits. 
When patients receive primary radiation without nutritional support 40% of patient loose 
more than 10% of their baseline weights, 40% of patients require hospitalization during 
the treatment with 20% of patients requiring therapy break, and 40% of these patients will 
require a gastrostomy placement to complete therapy. (3,4,20)  As expected 91% of 
patients who received radiation in addition to surgical resection required short term 
enteral support. However, this dependency was self-limited, and did not impact long 
term oral nutrition, evident by no difference at 1 year between the radiated or 
unirradiated (Table 2). 
A pharyngeal site was significant on univariate analysis, while flap reconstruction was 
significant on both univariate and multivariate analysis. Given the significant amount of 
dysfunction associated with these surgical procedures, this data validates our clinical 
expectation that these subsets benefit from prophylactic PEGs. Importantly, given the 
propensity of oral pharyngeal bacterial overgrowth in this patient subset and significant 
intra-oral tumor burden, we believe that the T-fastener technique should be used to 
prevent/reduce PEG site abscess and local cancer recurrence. We previously published that 
the T-fastener technique has a low rate of local infection and cancer recurrence in head and 
neck carcinoma population. (21) 
Chemotherapy was the only other significant factor on multivariate analysis. Although our 
series was small, the increasing use of chemotherapy in the management of the head and 
neck SCC population will dramatically increase this patient fraction requiring nutritional 
support. In our study almost half of chemotherapy patients required long-term support. We 
believe that prophylactic PEG placement should be part of the management discussion in 
patients receiving adjuvant or neoadjuvant chemotherapy. 
Importantly when PEG tubes are placed in this patient population, the usage of the T-
fastener technique is critical. Most of these patients are at high risk for PEG site infection 
and tumor implantation when the pull through technique is used in this patient population. 
We recently published that the rate of these complications can be significantly reduced by 
direct PEG placement with T-fastener strategy. 
This review confirmed the favorable current approach to prophylactic PEG tube in the head 
and neck cancer population. Aside from patients who present malnourished, prophylactic 
PEG tubes should be placed in all SCC head and neck cancer patients who have a 
pharyngeal primary tumor site, require flap reconstruction, undergo radiation therapy, 
and/or chemotherapy. 
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